• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production.

作者信息

Guo Yelei, Tong Chuan, Wu Zhiqiang, Lu Yuting, Wang Yao, Han Weidong

机构信息

Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.

出版信息

Cancer Biol Med. 2023 Nov 6;20(11):779-82. doi: 10.20892/j.issn.2095-3941.2023.0324.

DOI:10.20892/j.issn.2095-3941.2023.0324
PMID:37929324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10690879/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca40/10690879/f37061a42c90/cbm-20-779-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca40/10690879/f37061a42c90/cbm-20-779-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca40/10690879/f37061a42c90/cbm-20-779-g001.jpg

相似文献

1
Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production.抗原呈递细胞和嵌合抗原受体T细胞的相互激活通过持续高水平产生干扰素γ引发广泛的内源性抗肿瘤免疫反应。
Cancer Biol Med. 2023 Nov 6;20(11):779-82. doi: 10.20892/j.issn.2095-3941.2023.0324.
2
CAR T cells ignite antitumor immunity.嵌合抗原受体 T 细胞能引发抗肿瘤免疫。
Trends Immunol. 2023 Oct;44(10):748-750. doi: 10.1016/j.it.2023.08.002. Epub 2023 Aug 29.
3
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.CD40 配体修饰的嵌合抗原受体 T 细胞通过引发内源性抗肿瘤反应增强抗肿瘤功能。
Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
4
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity.疫苗增强的 CAR T 细胞与宿主免疫的串扰，以拒绝具有抗原异质性的肿瘤。
Cell. 2023 Jul 20;186(15):3148-3165.e20. doi: 10.1016/j.cell.2023.06.002. Epub 2023 Jul 5.
5
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.IFNγ 对于 CAR T 细胞介导的髓系细胞激活和内源性免疫诱导至关重要。
Cancer Discov. 2021 Sep;11(9):2248-2265. doi: 10.1158/2159-8290.CD-20-1661. Epub 2021 Apr 9.
6
Enterotoxins can support CAR T cells against solid tumors.肠毒素可支持 CAR T 细胞对抗实体瘤。
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25229-25235. doi: 10.1073/pnas.1904618116. Epub 2019 Nov 25.
7
Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.利用人工抗原呈递细胞生成用于过继性细胞治疗的抗肿瘤T细胞。
J Immunother. 2020 Apr;43(3):79-88. doi: 10.1097/CJI.0000000000000306.
8
Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces.利用工程化抗原呈递细胞表面激活和脱颗粒 CAR-T 细胞。
PLoS One. 2020 Sep 25;15(9):e0238819. doi: 10.1371/journal.pone.0238819. eCollection 2020.
9
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.嵌合抗原受体修饰的 T 细胞分泌检查点抑制剂增强癌症免疫治疗。
Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. doi: 10.1158/1078-0432.CCR-17-0867. Epub 2017 Sep 14.
10
GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.GD2 导向的 CAR T 与激活的 NK 细胞介导的 IFNγ 分泌克服了 MYCN 依赖性 IDO1 抑制，有助于神经母细胞瘤细胞的免疫逃逸。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001502.

引用本文的文献

1
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.针对卵巢癌腹膜癌病的间皮素靶向 CAR.CIK 淋巴细胞的三维动力学。
Cancer Immunol Immunother. 2024 Nov 2;74(1):6. doi: 10.1007/s00262-024-03860-w.

本文引用的文献

1
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity.疫苗增强的 CAR T 细胞与宿主免疫的串扰，以拒绝具有抗原异质性的肿瘤。
Cell. 2023 Jul 20;186(15):3148-3165.e20. doi: 10.1016/j.cell.2023.06.002. Epub 2023 Jul 5.
2
CD4 T cell-induced inflammatory cell death controls immune-evasive tumours.CD4 T 细胞诱导的炎症细胞死亡控制免疫逃避肿瘤。
Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14.
3
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
2022 年中国抗 CD19 嵌合抗原受体 T 细胞治疗 B 细胞非霍奇金淋巴瘤毒性管理临床专家共识及指南
Cancer Biol Med. 2023 Mar 2;20(2):129-46. doi: 10.20892/j.issn.2095-3941.2022.0585.
4
Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies.从较少的外周血中培养足够的嵌合抗原受体T细胞（CAR-T）来治疗B细胞恶性肿瘤。
Cancer Biol Med. 2021 Aug 14;18(4):1066-79. doi: 10.20892/j.issn.2095-3941.2021.0040.
5
IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.IFNγ 对于 CAR T 细胞介导的髓系细胞激活和内源性免疫诱导至关重要。
Cancer Discov. 2021 Sep;11(9):2248-2265. doi: 10.1158/2159-8290.CD-20-1661. Epub 2021 Apr 9.
6
CD103 cDC1 and endogenous CD8 T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function.CD103cDC1 和内源性 CD8 T 细胞对于提高过表达 CD40L 的 CAR-T 细胞抗肿瘤功能是必要的。
Nat Commun. 2020 Dec 2;11(1):6171. doi: 10.1038/s41467-020-19833-3.
7
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.优化的串联 CD19/CD20 CAR 工程化 T 细胞治疗难治/复发 B 细胞淋巴瘤。
Blood. 2020 Oct 1;136(14):1632-1644. doi: 10.1182/blood.2020005278.
8
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.嵌合抗原受体修饰的抗 EGFR T 细胞治疗转移性胰腺癌的 I 期临床试验
Cytotherapy. 2020 Oct;22(10):573-580. doi: 10.1016/j.jcyt.2020.04.088. Epub 2020 Jun 9.
9
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.采用表达树突状细胞生长因子 Flt3L 的 T 细胞过继细胞疗法可诱导表位扩展和抗肿瘤免疫。
Nat Immunol. 2020 Aug;21(8):914-926. doi: 10.1038/s41590-020-0676-7. Epub 2020 May 18.
10
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.肿瘤内龛位维持并分化具有干细胞样特征的 CD8+T 细胞。
Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.